88 related articles for article (PubMed ID: 22266863)
41. [Advances on molecular targets for squamous cell lung cancer targeted therapy].
Tao D; Shi Y; Han X
Zhonghua Bing Li Xue Za Zhi; 2015 Jun; 44(6):433-7. PubMed ID: 26704849
[No Abstract] [Full Text] [Related]
42. Pseudomesothelioma due to squamous cell lung cancer: An uncommon occurrence.
Tan BSM; Currie GP; Chapman A; Ragupathy S; Miller DR
J R Coll Physicians Edinb; 2024 May; ():14782715241258502. PubMed ID: 38813911
[No Abstract] [Full Text] [Related]
43. Necitumumab: a new therapeutic option for squamous cell lung cancer?
Pillai RN; Ramalingam SS
Transl Lung Cancer Res; 2014 Dec; 3(6):382-3. PubMed ID: 25806327
[No Abstract] [Full Text] [Related]
44. Impact of the use of antibiotics on the clinical response to immune checkpoint inhibitors in patients with non-small cell lung cancer.
Martinez-Mugica Barbosa C; Cercós Lletí AC; Pampín Sánchez R; Durán Román C; Terroba Alonso P; Fernández González B
Rev Esp Quimioter; 2022 Dec; 35(6):551-558. PubMed ID: 36164854
[TBL] [Abstract][Full Text] [Related]
45. Construction of a prognostic immune-related lncRNA model and identification of the immune microenvironment in middle- or advanced-stage lung squamous carcinoma patients.
Xue Q; Wang Y; Zheng Q; Chen L; Jin Y; Shen X; Li Y
Heliyon; 2022 May; 8(5):e09521. PubMed ID: 35663751
[TBL] [Abstract][Full Text] [Related]
46. USP28: Oncogene or Tumor Suppressor? A Unifying Paradigm for Squamous Cell Carcinoma.
Prieto-Garcia C; Tomašković I; Shah VJ; Dikic I; Diefenbacher M
Cells; 2021 Oct; 10(10):. PubMed ID: 34685632
[TBL] [Abstract][Full Text] [Related]
47. A curated target gene pool assisting disease prediction and patient-specific biomarker selection for lung squamous cell carcinoma.
Huang B; Zhong N; Cao H; Yu G
Oncol Lett; 2018 Oct; 16(4):5140-5146. PubMed ID: 30197682
[TBL] [Abstract][Full Text] [Related]
48. Molecular Targets in Non-Small Cell Lung Cancer.
Griffin R; Ramirez RA
Ochsner J; 2017; 17(4):388-392. PubMed ID: 29230123
[TBL] [Abstract][Full Text] [Related]
49. Interferon induced transmembrane protein 3 regulates the growth and invasion of human lung adenocarcinoma.
Zhang D; Wang H; He H; Niu H; Li Y
Thorac Cancer; 2017 Jul; 8(4):337-343. PubMed ID: 28544512
[TBL] [Abstract][Full Text] [Related]
50. Targeting the KRAS Pathway in Non-Small Cell Lung Cancer.
Tomasini P; Walia P; Labbe C; Jao K; Leighl NB
Oncologist; 2016 Dec; 21(12):1450-1460. PubMed ID: 27807303
[TBL] [Abstract][Full Text] [Related]
51. KRAS Mutation in Small Cell Lung Carcinoma and Extrapulmonary Small Cell Cancer.
Kodaz H; Taştekin E; Erdoğan B; Hacıbekiroğlu İ; Tozkır H; Gürkan H; Türkmen E; Demirkan B; Uzunoğlu S; Çiçin İ
Balkan Med J; 2016 Jul; 33(4):407-10. PubMed ID: 27606136
[TBL] [Abstract][Full Text] [Related]
52. PIAS3 expression in squamous cell lung cancer is low and predicts overall survival.
Abbas R; McColl KS; Kresak A; Yang M; Chen Y; Fu P; Wildey G; Dowlati A
Cancer Med; 2015 Mar; 4(3):325-32. PubMed ID: 25573684
[TBL] [Abstract][Full Text] [Related]
53. Rapid onset lung squamous cell carcinoma with prominent peritoneal carcinomatosis and an eosinophilic leukemoid reaction, with coexistence of the BRAF V600E and oncogenic KRAS G12A mutations: A case report.
Li B; Lu JC; He D; Wang J; Zhou H; Shen L; Zhang C; Duan C
Oncol Lett; 2014 Aug; 8(2):589-593. PubMed ID: 25013473
[TBL] [Abstract][Full Text] [Related]
54. Antitumor efficacy of the anti-interleukin-6 (IL-6) antibody siltuximab in mouse xenograft models of lung cancer.
Song L; Smith MA; Doshi P; Sasser K; Fulp W; Altiok S; Haura EB
J Thorac Oncol; 2014 Jul; 9(7):974-982. PubMed ID: 24922005
[TBL] [Abstract][Full Text] [Related]
55. Contrasting responses of non-small cell lung cancer to antiangiogenic therapies depend on histological subtype.
Larrayoz M; Pio R; Pajares MJ; Zudaire I; Ajona D; Casanovas O; Montuenga LM; Agorreta J
EMBO Mol Med; 2014 Apr; 6(4):539-50. PubMed ID: 24500694
[TBL] [Abstract][Full Text] [Related]
56. Identification of a subset of human non-small cell lung cancer patients with high PI3Kβ and low PTEN expression, more prevalent in squamous cell carcinoma.
Cumberbatch M; Tang X; Beran G; Eckersley S; Wang X; Ellston RP; Dearden S; Cosulich S; Smith PD; Behrens C; Kim ES; Su X; Fan S; Gray N; Blowers DP; Wistuba II; Womack C
Clin Cancer Res; 2014 Feb; 20(3):595-603. PubMed ID: 24284056
[TBL] [Abstract][Full Text] [Related]
57. Genetic insight and therapeutic targets in squamous-cell lung cancer.
Sos ML; Thomas RK
Oncogene; 2012 Nov; 31(46):4811-4. PubMed ID: 22266863
[TBL] [Abstract][Full Text] [Related]
58. [Advances of molecular targeted therapy in squamous cell lung cancer].
Ma L; Zhang S
Zhongguo Fei Ai Za Zhi; 2013 Dec; 16(12):671-5. PubMed ID: 24345494
[TBL] [Abstract][Full Text] [Related]
59. Discoidin domain receptor 2 signaling networks and therapy in lung cancer.
Payne LS; Huang PH
J Thorac Oncol; 2014 Jun; 9(6):900-4. PubMed ID: 24828669
[TBL] [Abstract][Full Text] [Related]
60. Adaptive responses to dasatinib-treated lung squamous cell cancer cells harboring DDR2 mutations.
Bai Y; Kim JY; Watters JM; Fang B; Kinose F; Song L; Koomen JM; Teer JK; Fisher K; Chen YA; Rix U; Haura EB
Cancer Res; 2014 Dec; 74(24):7217-7228. PubMed ID: 25348954
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
